voyager therapeutics investor relations

Vision, Mission, & Strategy

Management Team

Board of Directors

Scientific Advisory Board

Core Values

• VY-TAU01 for Alzheimer’s

• Alzheimer’s early research

• SOD1 for ALS

Patient Resources

Partnerships

TRACER Platform

Non-Viral Delivery

Publications & Presentations

Press Releases

Events & Presentations

Stock Information

Shareholder Services

Job Openings

Our Community

Mission & Values

Disclosures

Release Details

Voyager therapeutics to present at multiple virtual investor conferences.

LEXINGTON, Mass. , June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024 , at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 , at 7:00 a.m. ET .

Webcasts of the presentations may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com . A replay of the webcasts will be archived on the Company's website for at least 30 days.

About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG ; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com .

Voyager Therapeutics ® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Brooke Shenkin , [email protected]

Source: Voyager Therapeutics, Inc.

Vision, Mission, & Strategy

Management Team

Board of Directors

Scientific Advisory Board

Core Values

• VY-TAU01 for Alzheimer’s

• Alzheimer’s early research

• SOD1 for ALS

Patient Resources

Partnerships

TRACER Platform

Non-Viral Delivery

Publications & Presentations

Press Releases

Events & Presentations

Stock Information

Shareholder Services

Job Openings

Our Community

Mission & Values

Disclosures

Release Details

Voyager therapeutics reports third quarter 2021 financial and operating results.

License option agreement with Pfizer provides Voyager $30M up front and up to $600M in potential exercise fees and milestone payments plus royalties in exchange for access to TRACER™ novel capsids for use with two Pfizer transgenes in neurologic and cardiovascular disease

TRACER platform identifies AAV9 and AAV5 capsid variants with broad CNS tropism and neuronal and glial cell targeting in non-human primates

Preclinical data demonstrate GBA1 gene therapy achieved widespread CNS distribution and sustained correction of GCase activity in multiple brain regions in mice

CAMBRIDGE, Mass. , Nov. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today reported third quarter 2021 financial and operating results.

Michael Higgins , interim CEO of Voyager. “The licensing transaction with Pfizer showcases TRACER’s ability to produce not only enhanced blood-brain barrier penetrant capsids, but also novel capsids with enhanced tropism for cardiac muscle, offering promise to unlock the fullest potential of gene therapies for a wide array of diseases. We’ve retained all rights to our capsid library outside of their use with two particular Pfizer transgenes, and we believe there is significant opportunity for similar transactions leveraging the entirety of our libraries for other targets inside and outside of the CNS.”

Glenn Pierce , M.D., Ph.D., interim CSO of Voyager. “In parallel, we’re advancing an innovative gene therapy pipeline leveraging our novel TRACER capsids. Preclinical data from our GBA1 gene replacement program illustrates the potential of a single-dose, IV-administered therapy to significantly raise target protein levels in the CNS, potentially impacting Parkinson’s disease, Lewy body dementia, and Gaucher disease.”

Pfizer License Option Agreement Supports TRACER Platform Potential for Multiple Therapeutic Areas

• In October, Voyager and Pfizer Inc. (NYSE: PFE) entered an agreement through which Pfizer may exercise options to license novel capsids generated from Voyager’s RNA-driven TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) screening technology. Under the agreement, Pfizer may evaluate novel TRACER capsids and exercise options to license up to two capsids for transgene-exclusive Pfizer gene therapy programs for neurologic and cardiovascular disease associated with those transgenes.
• The Pfizer transgenes are distinct from those planned for Voyager’s internal pipeline, and Voyager retains global rights to all TRACER capsids for use with other transgenes and to all other applications of its TRACER technology.
• Voyager received a $30 million upfront payment from Pfizer and is entitled to receive up to $20 million in exercise fees in aggregate for two options, exercisable by Pfizer within 12 months of signing. Voyager is also eligible to earn up to $580 million in total development, regulatory, and commercial milestones associated with licensed products incorporating the two undisclosed Pfizer transgenes together with a Voyager licensed capsid. Voyager is also eligible to receive mid- to high-single-digit tiered royalties based on net sales of Pfizer’s products incorporating the licensed capsids.

TRACER Identifies AAV9 and AAV5 Capsid Variants with Broad CNS Tropism, Neuronal and Glial Cell Targeting; Screening Campaigns Advancing

• Voyager is performing further screening with its TRACER platform to identify additional proprietary AAV9- and AAV5-derived capsids targeting multiple tissue and cell types for use in gene therapies to treat a broad range of diseases.
• Numerous promising capsids have been identified from these screens, which are undergoing rigorous testing across multiple non-human primate and rodent species to evaluate their clinical translatability.
• In addition to capsids with substantially enhanced CNS tropism for neurons in non-human primates, a new array of TRACER AAV9 and AAV5 variants show robust CNS targeting in both non-human primates and rodents and demonstrate a strong tropism for glial cells, which may enable more effective targeting of certain CNS diseases.
• Capsid candidates derived from AAV5 present significant potential advantages in terms of lower prevalence of preexisting neutralizing antibodies in the general population and manufacturing. In addition, these variants demonstrate cross-species translatability among primates and rodents. Initial testing on these AAV5-derived capsids has demonstrated approximately 20-fold improvements in brain transduction compared with AAV9 in non-human primates.
• As previously disclosed , initial data from AAV9-derived TRACER capsids demonstrated robust delivery across the blood-brain barrier and widespread CNS transduction in non-human primates compared to AAV9 delivery following intravenous (IV) administration. In addition, a proprietary capsid displayed strong cardiac transduction and significant dorsal root ganglia detargeting in non-human primates, which may avoid dose-related toxicities associated with AAV9 delivery.

Positive Preclinical Data from GBA1 Program

• Voyager continues to advance its early-stage programs including multiple programs utilizing proprietary AAV capsids derived from the TRACER platform. Voyager believes these capsids may enable new, best-in-class gene therapy programs with systemic IV delivery and lower risk of dose-limiting toxicities. Pipeline programs include those for Huntington’s disease, monogenic ALS (SOD1), spinal muscular atrophy, and diseases linked to GBA1 mutations, including Parkinson’s disease, Lewy body dementia, and Gaucher disease.
• Voyager presented initial preclinical data from its GBA1 gene replacement program at the virtual 2021 Annual Congress of the European Society of Gene & Cell Therapy , Oct. 19-22, 2021 . The results demonstrated that an IV-administered gene replacement therapy using a proprietary AAV capsid achieved widespread distribution in the CNS and peripheral tissues, and raised levels of the deficient GCase enzyme by 300% - 660% over endogenous levels in a mouse model. By comparison, increases of 30% - 50% are expected to be clinically impactful. These data support the potential of a novel therapeutic approach for diseases associated with GBA mutations, including Parkinson’s disease, Lewy body dementia, and Gaucher disease.

Upcoming Events and Presentations

• Society for Neuro-Oncology 26 th Annual Meeting, Nov. 18-21, 2021

Third Quarter 2021 Financial Results

• Collaboration Revenues: Collaboration revenue was $1.5 million for the third quarter of 2021, compared to collaboration revenue of $117.8 million for the same period of 2020. The decrease in collaboration revenue was largely due to a reduction of revenue related to research services and cost reimbursements from the collaborations with Neurocrine and AbbVie. In February 2021 , Neurocrine provided notice that effective August 2, 2021 it was terminating its participation in the VY-AADC program for Parkinson’s disease under the collaboration agreement between Voyager and Neurocrine, and that wind-down activities, including the termination by Neurocrine of its support for ongoing development activities for the VY-AADC program, would commence immediately. Additionally, the collaborations with AbbVie were terminated in August 2020 and resulted in recognition of $47.2 million of revenue related to the collaboration targeting tauopathies and $59.4 million of revenue related to the collaboration targeting synucleinopathies during the quarter ended September 30, 2020 , as Voyager had no further service obligations at that time.
• Net Loss: Net loss was $25.1 million for the third quarter of 2021, compared to net income of $85.6 million for the same period of 2020.
• R&D Expenses: Research and development expenses were $17.9 million for the third quarter of 2021, compared to $25.0 million for the same period in 2020. The decrease in R&D expenses was primarily related to lower research and development employee-related expenses as well as manufacturing and clinical expenses for the VY-AADC program for Parkinson’s disease.
• G&A Expenses: General and administrative expenses were $8.7 million for the third quarter of 2021, compared to $8.3 million for the same period in 2020. The increase in G&A expenses was primarily related to increased employee-related expenses in connection with a reduction in force and facility costs.
• Cash Position: Cash, cash equivalents, and marketable debt securities as of September 30, 2021 were $121.5 million .

Financial Guidance

• Based on Voyager’s current operating plan and excluding any potential financing or business development activities in 2021, Voyager anticipates cash, cash equivalents, and marketable debt securities will be greater than $130 million at the end of 2021.

About the TRACER™  AAV Capsid Discovery Platform Voyager’s TRACER™ system is a broadly applicable, RNA-based functional screening platform that allows for rapid in vivo evolution of AAV capsids with enhanced tropisms and cell- and tissue-specific transduction properties in multiple species, including non-human primates (NHPs). Initial data from the first of many libraries screened in NHPs demonstrated the proprietary capsid variants effectively penetrated the blood-brain barrier and achieved widespread biodistribution and transduction of multiple regions of the brain. Separate results have demonstrated the ability of certain capsids to transduce cardiac muscle and to de-target the dorsal root ganglia. Voyager is proceeding with additional capsid campaigns derived from unique capsid serotypes to identify novel AAV vectors optimized for specific therapeutic applications.

About Voyager Therapeutics Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the technology to treat devastating diseases. Proprietary capsids born from the Company’s TRACER™ screening platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the limitations of conventional gene therapy vectors across neurologic disorders and other therapeutic areas. voyagertherapeutics.com          LinkedIn          Twitter

Forward-Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “undoubtedly,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements.

For example, all statements Voyager makes regarding Voyager’s ability to continue to identify and develop proprietary capsids from its TRACER AAV screening platform; Voyager’s ability to identify and develop proprietary capsids from its TRACER AAV screening platform with increased transgene expression, increased blood-brain barrier penetration and increased biodistribution compared to conventional AAV5 and AAV9 capsids; Voyager’s ability to utilize its novel proprietary capsids in its own product development programs; Voyager’s ability to attract parties to license its novel proprietary capsids or to participate with Voyager in research and development collaborations utilizing its novel proprietary capsid; Voyager’s ability to advance its AAV-based gene therapy programs; Voyager’s ability to perform its obligations under its license option agreement with Pfizer; Voyager’s entitlement to receive upfront, milestone and royalty based fees from Pfizer under the license option agreement; Voyager’s ability to maintain its current partnerships and collaborations and to enter into new partnerships or collaborations; and Voyager’s ability to generate sufficient cash resources to enable it to continue to identify and develop proprietary capsids from its TRACER AAV screening platform are forward looking.

All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the severity and length of the COVID-19 health crisis, the imposition of governmental controls and guidance addressing the COVID health crisis, and the financial and human resources available to Voyager to manage the COVID-19 health crisis; the continued development of various technology platforms, including Voyager’s TRACER platform; Voyager’s scientific approach and general development progress; the ability to attract and retain talented contractors and employees, including key scientists and business leaders; the ability to create and protect intellectual property; the sufficiency of cash resources; the possibility or the timing of the exercise of development, commercialization, license and other options under the Pfizer license option agreement and other collaborations; the ability of Voyager to negotiate and complete licensing or collaboration agreements on terms acceptable to Voyager and third parties; and the availability or commercial potential of Voyager’s product candidates.

These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission , as updated by its subsequent filings with the Securities and Exchange Commission . All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Scott Santiamo   [email protected]

Selected Financial Information ($-amounts in thousands, except per share data) (Unaudited)

Source: Voyager Therapeutics, Inc.

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• Biden Economy
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds
• Top Mutual Funds
• Highest Open Interest
• Highest Implied Volatility
• Stock Comparison
• Advanced Charts
• Currency Converter
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Mutual Funds
• Credit Cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Student Loans
• Personal Loans
• Car Insurance
• Mortgage Calculator
• Morning Brief
• Market Domination
• Market Domination Overtime
• Asking for a Trend
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Voyager therapeutics reports first quarter 2024 financial and operating results.

- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks -

- Development candidates selected for Neurocrine-partnered GBA1 and Friedreich’s Ataxia gene therapy programs; potential for three gene therapies, including SOD1-ALS, to enter the clinic in 2025 -

- Appointed neurology clinical development expert Toby Ferguson, M.D., Ph.D., as Chief Medical Officer -

- Strong cash position of approximately $400 million as of March 31, 2024; expected to provide runway through multiple clinical data readouts into 2027 -

LEXINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today reported first quarter 2024 financial and operating results.

“We have obtained IND clearance for our anti-tau antibody VY-TAU01 for Alzheimer’s disease, and we expect to dose the first subject in our single ascending dose trial in healthy volunteers in the coming weeks,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Our gene therapy pipeline is also advancing, with development candidates selected in the GBA1 and Friedreich’s Ataxia programs partnered with Neurocrine, as well as in our wholly-owned SOD1-ALS program. We expect to achieve IND filings for all three of these gene therapy programs in 2025. We maintain a strong cash position of approximately $400 million at quarter-end, with runway into 2027, which we anticipate will enable us to reach multiple data readouts in 2025 and 2026.”

First Quarter 2024 and Recent Highlights

Obtained IND clearance for VY-TAU01 for Alzheimer’s disease: Received clearance of the Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration (FDA) for VY-TAU01, an anti-tau antibody for the treatment of Alzheimer’s disease.

Development candidate selected in GBA1 gene therapy program: Announced that the joint steering committee with collaborator Neurocrine Biosciences selected a lead development candidate for the GBA1 gene therapy program for the treatment of Parkinson’s disease and other GBA1-mediated diseases, triggering a $3 million milestone payment to Voyager.

Development candidate selected in FXN gene therapy program: Announced that the joint steering committee with collaborator Neurocrine Biosciences selected a lead development candidate for the FXN gene therapy program for the treatment of Friedreich’s Ataxia, triggering a $5 million milestone payment to Voyager.

Toby Ferguson, M.D., Ph.D., appointed as Chief Medical Officer: Dr. Ferguson is an experienced biotechnology executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare diseases.

Strategic collaboration and capsid license agreement with Novartis: Announced a strategic collaboration and capsid license agreement with Novartis Pharma AG to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA). Novartis paid Voyager $80 million of consideration up front and $20 million for the purchase of newly issued equity in Voyager. Voyager is eligible to receive up to $1.2 billion in preclinical, development, regulatory and sales milestones, as well as tiered royalties on global net sales of products incorporating Voyager’s TRACER™ capsids.

Completion of public offering: Completed an underwritten public offering of shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) for aggregate gross proceeds of approximately $100 million.

Presented data at AD/PD 2024 and ASGCT 2024:

2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2024): Presented data demonstrating robust reductions in human tau messenger RNA (mRNA) and protein across the brain following a single intravenous (IV) administration of a tau silencing gene therapy candidate in mice expressing human tau. Also presented data demonstrating that VY-TAU01 was well-tolerated following IV administration in non-human primates (NHPs).

American Society of Gene & Cell Therapy’s (ASGCT) 27th annual meeting: Presented a broad set of translational data, including new data demonstrating enhanced brain tropism of second-generation TRACER-derived AAV capsids, translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer’s disease and ALS.

Anticipated Upcoming Milestones

VY-TAU01 anti-tau antibody for Alzheimer’s disease: Voyager expects to dose the first subject in a Phase 1a single ascending dose trial in healthy volunteers in the coming weeks and initiate a Phase 1b multiple ascending dose trial in patients with early Alzheimer’s disease in 2025. The multiple ascending dose trial has the potential to generate initial data for slowing the spread of pathological tau via tau PET imaging in 2026.

VY9323 SOD1 silencing gene therapy program for ALS: Voyager expects to file an IND in mid-2025 and initiate a Phase 1 clinical trial in ALS patients. The Phase 1 trial has the potential to generate proof-of-concept data based on biomarkers.

Partnered programs: Voyager and Neurocrine Biosciences expect to file INDs for the GBA1 and Friedreich’s Ataxia gene therapy programs in 2025.

First Quarter 2024 Financial Results

Collaboration Revenues: Voyager had collaboration revenue of $19.5 million for the first quarter of 2024, compared to $150.5 million for the same period in 2023. The decrease was primarily due to the first quarter 2023 recognition of $69.5 million from the 2023 Neurocrine Collaboration Agreement and $79.0 million from Novartis’ exercise of two capsid options.

Net (Loss) Income: Net loss was $11.3 million for the first quarter of 2024, compared to net income of $124.0 million for the same period in 2023. The decrease is primarily due to reduced collaboration revenue recognized in the first quarter of 2024, as discussed above.

R&D Expenses: Research and development expenses were $27.1 million for the first quarter of 2024, compared to $18.6 million for the same period in 2023. The increase in R&D expenses was primarily a result of increased program-related spending, particularly manufacturing and IND-enabling studies for the VY-TAU01 anti-tau antibody program, the VY9323 SOD1-ALS gene therapy program, and the initiation of spend on the Novartis HD program during the first quarter of 2024, along with increased headcount costs.

G&A Expenses: General and administrative expenses were $8.6 million for the first quarter of 2024, compared to $9.0 million for the same period in 2023.

Cash Position: Cash, cash equivalents and marketable securities as of March 31, 2024, were $400.5 million.

Financial Guidance

Voyager is committed to maintaining a strong balance sheet that supports the advancement and growth of its platform and pipeline. Voyager continues to assess its planned cash needs both during the current period and in future periods. We expect our cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement for development costs under the Neurocrine and Novartis collaborations, certain near-term milestones, and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2027.

Conference Call

Voyager will host a conference call and webcast today at 4:30 p.m. ET to discuss first quarter 2024 financial and operating results. To participate via telephone and join the call live, please register in advance here: https://register.vevent.com/register/BI1f6af80e7a614ca7925cbad2f35a55c6 . Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com , and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

About the TRACER™ Capsid Discovery Platform

Voyager’s TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable, RNA-based screening platform that enables rapid discovery of novel AAV capsids to enable gene therapy. Voyager has leveraged TRACER to create multiple families of novel capsids that, following intravenous delivery in preclinical studies, harness the extensive vasculature of the central nervous system (CNS) to cross the blood-brain barrier and transduce a broad range of CNS regions and cell types. In cross-species preclinical studies (rodents and multiple non-human primate species), intravenous delivery of TRACER-generated capsids resulted in widespread payload expression across the CNS at relatively low doses, enabling selection of multiple development candidates in Voyager’s wholly-owned and partnered gene therapy programs for neurologic diseases.

About Voyager Therapeutics

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com .

Voyager Therapeutics ® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “expect,” “will,” “believe,” “anticipate,” “potential,” “trigger” or “continue,” and other similar expressions are intended to identify forward-looking statements.

For example, all statements Voyager makes regarding Voyager’s ability to advance its AAV-based gene therapy programs and tau antibody program, including expectations for Voyager’s achievement of preclinical and clinical development milestones for its potential development candidates such as IND filings, the initiation of clinical trials, and generation of clinical data and proof-of-concept; Voyager’s ability to advance gene therapy product candidates under the Neurocrine and Novartis collaborations; Voyager’s anticipated financial results, including the anticipated receipt by Voyager of revenues or reimbursement payments from collaboration partners; and Voyager’s cash runway and ability to generate sufficient cash resources to enable it to continue its business and operations are forward looking.

All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the expectations and decisions of regulatory authorities; the timing, initiation, conduct and outcomes of Voyager’s preclinical and clinical studies; the availability of data from clinical trials; the availability or commercial potential of product candidates under collaborations; the willingness and ability of Voyager's collaboration partners to meet obligations under collaboration agreements with Voyager; the continued development of Voyager’s technology platforms, including Voyager’s TRACER platform and its antibody screening technology; Voyager’s scientific approach and program development progress, and the restricted supply of critical research components; the development by third parties of capsid identification platforms that may be competitive to Voyager’s TRACER capsid discovery platform; Voyager’s ability to create and protect intellectual property rights associated with the TRACER capsid discovery platform, the capsids identified by the platform, and development candidates for Voyager’s pipeline programs; the possibility or the timing of Voyager’s receipt of program reimbursement, development or commercialization milestones, option exercise, and other payments under Voyager’s existing licensing or collaboration agreements; the ability of Voyager to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to Voyager and the third parties; the success of programs controlled by third party collaboration partners in which Voyager retains a financial interest, and the success of Voyager’s product candidates; the ability to attract and retain talented directors, employees, and contractors; and the sufficiency of cash resources to fund its operations and pursue its corporate objectives.

These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Trista Morrison, NACD.DC, [email protected] Investors: Adam Bero, Ph.D., [email protected] Media: Brooke Shenkin, [email protected]

GAAP vs. Non-GAAP Financial Measures Voyager’s financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent revenue and expenses as reported to the Securities and Exchange Commission. Voyager has provided in this release certain financial information that has not been prepared in accordance with GAAP, including net collaboration revenue and net research and development expenses, which exclude the impact of reimbursement by Neurocrine Biosciences (Neurocrine) for expenses we incur in conducting preclinical development activities under our collaboration agreements. Management uses these non-GAAP measures to evaluate the Company’s operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in its business. Management believes that such non-GAAP measures are important in comparing current results with prior period results and are useful to investors and financial analysts in assessing the Company’s operating performance. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation. The non-GAAP measures give investors and financial analysts a better understanding of our net revenue and net research and development expenses without the pass-through impact of Neurocrine costs. The non-GAAP financial information presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures set forth below.

Note 1: Under the Company's existing collaboration agreements with Neurocrine and Novartis, Neurocrine and Novartis have agreed to be responsible for all costs the Company incurs in conducting preclinical development activities for certain collaboration programs, in accordance with joint steering committee agreed upon workplans and budgets. Reimbursable research and development services performed during the period are captured within collaboration revenue and research and development expenses in the Company's consolidated statements of operations. During the three months ended March 31, 2024, we incurred $3.2 million of reimbursable research and development services recorded within collaboration revenue and research and development expenses. During the three months ended March 31, 2023, we incurred $0.3 million of reimbursable research and development services recorded within collaboration revenue and research and development expenses.

We couldn’t find any results matching your search.

Please try using other words for your search or explore other sections of the website for relevant information.

We’re sorry, we are currently experiencing some issues, please try again later.

Our team is working diligently to resolve the issue. Thank you for your patience and understanding.

Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates

CAMBRIDGE, Mass. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its third quarter 2020 financial results, program progress and corporate updates.

“During the third quarter, we took important steps to advance our lead programs for Parkinson’s disease and Huntington’s disease with the presentation of positive long-term clinical results and the filing of an IND, respectively. Together with our partner, Neurocrine, we are currently focused on resuming enrollment in the RESTORE-1 clinical trial for Parkinson’s disease pending the requested review and assessment of patient imaging data by the DSMB . For our Huntington’s disease program, the FDA has provided clarity regarding the additional information it is requesting pursuant to our IND filing. We plan to work with the FDA to respond to these requests to allow for an IND clearance and the start of VY-HTT01’s clinical evaluation,” said Andre Turenne , President and CEO of Voyager. “We look forward to continuing our progress on these two important programs, along with our broadening AAV gene therapy portfolio to treat severe neurological diseases.”

Recent Program and Corporate Highlights

VY-AADC (NBIb-1817) for Parkinson’s Disease

• Voyager and Neurocrine Biosciences (Neurocrine) are developing VY-AADC (NBIb-1817) as a one-time AAV-based gene therapy encoding the gene for human AADC that is designed to help produce the AADC enzyme in brain cells where it can convert levodopa to dopamine. VY-AADC (NBIb-1817) is administered into the brain using magnetic resonance imaging (MRI)-facilitated targeted delivery.
• In September 2020 , Voyager and Neurocrine presented new positive long-term, three-year data from the PD-1101 Phase 1b trial, and two-year data from the PD-1102 trial, demonstrating that a one-time treatment with VY-AADC (NBIb-1817) showed sustained improvement in motor function including greater mean ON time without troublesome dyskinesia, reduction in Unified Parkinson’s Disease Rating Scale (UPDRS) Part III scores, and reduction in the amount of Parkinson’s disease medications in these patients. The data were presented at the MDS Virtual Congress 2020.
• In November 2020 , the Data Safety Monitoring Board (DSMB) for the RESTORE-1 Phase 2 clinical trial reviewed certain patient imaging data from the ongoing trial and recommended a pause in the dosing of patients in RESTORE-1 pending review by the DSMB of additional data. As previously announced, trial sites participating in RESTORE-1 are not currently screening and enrolling patients as a result of the COVID-19 pandemic. In response to the DSMB’s recommendation, Voyager and Neurocrine have decided to delay the planned resumption of patient screening in the RESTORE-1 trial until the DSMB is able to complete its evaluation. The DSMB is expected to consider additional patient data before year-end. Neurocrine is preparing an expedited safety report that will be submitted to the FDA within the 15-day reporting window.

VY-HTT01 for Huntington’s Disease

• Voyager is developing VY-HTT01 as a one-time AAV-based gene therapy treatment designed to knock down expression of the HTT gene. Voyager’s approach is focused on delivering VY-HTT01 directly into the brain and targeting a reduction of the levels of HTT protein in the striatum and cortex to potentially slow the progression of both motor and cognitive symptoms.
• In September 2020 , Voyager submitted an IND application for VY-HTT01 in Huntington’s disease, and in October, Voyager was notified that the IND had been placed on clinical hold pending the resolution of certain CMC information requests. Voyager recently received written feedback from the FDA requesting additional information on specific CMC topics, including drug-device compatibility and drug substance and product characterization. Voyager plans to work closely with the agency to resolve the additional information request in a timely manner.
• Following clearance of the IND by the FDA, Voyager expects to begin a Phase 1b clinical trial of VY-HTT01 in Huntington’s disease patients.

Novel AAV Capsid Discovery Program

• Voyager continues to progress its efforts in the discovery and engineering of novel AAV capsids with the potential to overcome the limitations of existing capsids, including greater blood-brain barrier (BBB) penetrance following IV administration. Voyager is leveraging its proprietary TRACER™ platform to facilitate the selection of AAV capsids with significantly improved BBB crossing and cell-specific transduction properties.
• Voyager is currently engaged in advanced non-human primate studies to further characterize and select novel AAV capsids with improved properties offering the potential for therapeutic applications in neurological disorders.

Recent Corporate Updates

• Voyager recently made key appointments of leaders across several functional areas. These include the appointments of Michelle Quinn Smith as Chief Human Resources Officer, Diana M. Collazo , Ph.D., J.D. as Chief Patent Counsel and Claire Sampson , Ph.D. as Vice President, Global Regulatory Affairs.
• Voyager recently appointed Nancy Vitale as an independent director to its Board of Directors, effective as of September 15, 2020 . Ms. Vitale brings more than 25 years of business and human resources experience to Voyager’s Board. She is a former Senior Vice President and Chief Human Resource Officer at Genentech , a member of the Roche Group.

Third Quarter 2020 Financial Results

• Collaboration Revenues: Voyager recorded collaboration revenue of $117.8 million for the third quarter of 2020, compared to collaboration revenue of $20.4 million for the same period of 2019. The increase in collaboration revenue was a result of the termination of the AbbVie collaborations in August 2020 and the subsequent recognition of all remaining deferred amounts under the agreements.
• Net Income: Net income was $85.6 million for the third quarter of 2020, compared to a net loss of $15.0 million for the same period of 2019.
• R&D Expenses: Research and development expenses were $25.0 million for the third quarter of 2020, compared to $29.8 million for the same period in 2019. The decrease in R&D expenses was primarily related to lower external costs for services supporting Voyager’s clinical and preclinical pipeline programs.
• G&A Expenses: General and administrative expenses were $8.3 million for the third quarter of 2020, compared to $8.5 million for the same period in 2019. The decrease in G&A expenses was primarily attributable to a decrease in professional fees supporting Voyager’s pipeline programs.
• Cash Position: Cash, cash equivalents and marketable debt securities as of September 30, 2020 were $200 million .

Financial Guidance

• Based on the Company’s current operating plan, Voyager anticipates cash, cash equivalents and marketable debt securities will be between $150 million and $170 million at the end of 2020.
• Voyager expects that its cash, cash equivalents and marketable debt securities, as well as amounts expected to be received for reimbursement of development costs from Neurocrine Biosciences, will be sufficient to meet Voyager’s projected operating expenses and capital expenditure requirements into mid-2022.

About Voyager Therapeutics Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia, and other severe neurological diseases. For more information on Voyager Therapeutics , please visit the company’s website at www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.

Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Forward-Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “undoubtedly,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements Voyager makes regarding Voyager’s ability to deliver patient imaging data to the DSMB for the RESTORE-1 Phase 2 clinical trial, the review of such data by the DSMB prior to year-end, and  pending the DSMB’s evaluation of such data the resumption of enrollment in the RESTORE-1 Phase 2 clinical trial; the submission by Neurocrine Biosciences of an expedited safety report relating to the RESTORE-1 clinical trial in a timely manner; Voyager’s efforts to work with the FDA to resolve additional information requests relating to the IND application for VY-HTT01, the clearance of the VY-HTT01 IND application by the FDA and the initiation of a Phase 1b clinical trial of VY-HTT01; Voyager’s continuing efforts in the discovery and engineering of novel AAV capsids, including progressing non-human primate studies of selected novel capsids; the contributions that will be made to Voyager by key senior level officers and a new member to the Voyager Board of Directors; the timing, progress, activities, goals and reporting of results of Voyager’s preclinical programs and clinical trials and its research and development programs; the potential clinical utility of its product candidates; Voyager’s ability to add new programs to its pipeline; the regulatory pathway of, and the timing or likelihood of its regulatory filings and approvals for, any of its product candidates; Voyager’s anticipated financial results, including Voyager’s available cash, cash equivalents and marketable debt securities; Voyager’s ability to fund its operating expenses with its current cash, cash equivalents and marketable debt securities through a stated time period; and the ability of Voyager to maintain a high level of business critical activity and maintain a level of scientific leadership during the COVID-19 health crisis are forward looking statements.

All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the ability to provide imaging data to the DSMB for the RESTORE-1 Phase 2 clinical trial, and the ability for the DSMB to complete its evaluation and to resolve questions that may exist regarding such patient data; the ability for Voyager to meet the information requests of, and to resolve questions raised by, the FDA relating to the IND application for VY-HTT01; the ability of Voyager to progress its research and engineering program for novel capsids and to conduct non-human primate studies; the initiation and conduct of preclinical studies and clinical trials; the availability of data from preclinical studies and clinical trials, and the ability to effectively present such data; Voyager’s scientific approach and general development progress; the ability to attract and retain talented contractors and employees; the ability to create and protect intellectual property; the sufficiency of cash resources; the possibility or the timing of the exercise of development, commercialization, license and other options under collaborations; the commercial potential of Voyager’s product candidates; the severity and length of the COVID-19 health crisis, the imposition of governmental controls and guidance addressing the COVID health crisis; and the financial and human resources available to Voyager to manage the COVID-19 health crisis. These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s Annual Report on Form 10-K filed with the Securities and Exchange Commission , as updated by its subsequent filings with the Securities and Exchange Commission . All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investors: Paul Cox VP, Investor Relations857-201-3463 [email protected]

Media: Sheryl Seapy W2Opure949-903-4750 [email protected]

Selected Financial Information ($-amounts in thousands, except per share data) (Unaudited)

In This Story

To add symbols:

• Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
• Copy and paste multiple symbols separated by spaces.

These symbols will be available throughout the site during your session.

Your symbols have been updated

Edit watchlist.

• Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.

Opt in to Smart Portfolio

Smart Portfolio is supported by our partner TipRanks. By connecting my portfolio to TipRanks Smart Portfolio I agree to their Terms of Use .

• Get 7 Days Free

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc.

“Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurotherapeutics based on genetically-validated targets,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Nathan’s highly differentiated background integrates operational and strategic leadership, a deep understanding of value creation in the life sciences, and expertise in neuroscience, which will be critical as we advance additional programs into the clinic and build a multi-modality neurotherapeutics company.”

As CFO at Vor Bio, Jorgensen oversaw finance, communications, facilities, GMP, and IT and raised over $400 million in public and private financings. Prior to this, he managed global public and private healthcare investing, including in early-stage biotech companies, for the Qatar Investment Authority, the sovereign wealth fund of the State of Qatar. Previously, Jorgensen led pharma and biotech investing efforts on the all-cap equity healthcare team at Calamos Investments LLC, a diversified global investment firm. Before joining Calamos, he covered mid- and large-cap biotech companies as an equity research analyst at Stifel, Nicolaus & Company, Incorporated. Prior to entering the financial sector, Jorgensen investigated the pathobiology of Parkinson’s disease as a postdoctoral scientist at the Columbia University Irving Medical Center. He received his MBA from the Cornell SC Johnson College of Business, his Ph.D. in neuroscience from the University of Minnesota, and his B.A. from St. John’s University.

“Voyager is advancing a suite of transformative neurogenetic medicines, with multiple opportunities to create value for patients and for shareholders,” said Jorgensen. “I am excited about the possibilities offered by Voyager’s differentiated platform, along with its unparalleled team in the field of neuroscience. The pipeline is poised to tackle the delivery hurdles that have held back progress in neurology, and I look forward to applying my strategic financial expertise to enable the team to execute and deliver on the promise of its tremendous science.”

About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com .

Voyager Therapeutics ® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Forward-Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “potential,” “anticipate,” “expect,” “will,” “may,” and other similar expressions are intended to identify forward-looking statements.

For example, all statements Voyager makes regarding the timing and effective date of the appointment of Dr. Jorgensen, the contributions Dr. Jorgensen may make in his role with the Company, and Voyager’s ability to advance additional programs into the clinic and build a multi-modality neurotherapeutics company are forward looking.

All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the continued development of Voyager’s technology platforms, including Voyager’s TRACER platform and its antibody screening technology; the ability to initiate and conduct preclinical studies in animal models; the development by third parties of capsid identification platforms that may be competitive to Voyager’s TRACER capsid discovery platform; Voyager’s ability to create and protect intellectual property rights associated with the TRACER capsid discovery platform, the capsids identified by the platform, and development candidates for Voyager’s pipeline programs; the initiation, timing, conduct and outcomes of Voyager’s preclinical and clinical studies; the possibility or the timing of Voyager’s receipt of program reimbursement, development or commercialization milestones, option exercise, and other payments under Voyager’s existing licensing or collaboration agreements; the ability of Voyager to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to Voyager and the third parties; the ability to attract and retain talented directors, employees, and contractors; and the sufficiency of cash resources to fund its operations and pursue its corporate objectives.

These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contacts Trista Morrison, NACD.DC, [email protected] Investors: Adam Bero, Ph.D., [email protected] Media: Brooke Shenkin, [email protected]

Market Updates

After earnings, is broadcom stock a buy, a sell, or fairly valued, 4 wide-moat stocks to buy for the long term while they’re undervalued today, markets brief: four stocks made up 80% of the gains. can it last, is it time to ditch your money market fund for longer-term bonds, what’s happening in the markets this week, 4 reasons why today’s stock market is delivering impressive performance, what does nvidia’s stock split mean for investors, 5 undervalued stocks to buy as their stories play out, stock picks, micron stock soars with the ai boom—is it a buy or a sell, with a 4% dividend yield and significant growth potential, this stock is a buy, 10 stocks the best fund managers have been buying, ge aerospace stock has skyrocketed 86%. is it a buy, 2 undervalued dividend stocks the best managers are buying, tesla: shareholder vote reduces key person risk, after earnings, is crowdstrike stock a buy, a sell, or fairly valued, adobe’s strong quarterly results drive share gains, sponsor center.

Vision, Mission, & Strategy

Management Team

Board of directors, scientific advisory board.

• VY-TAU01 for Alzheimer’s

• Alzheimer’s early research

• SOD1 for ALS

Patient Resources

Partnerships

TRACER Platform

Non-Viral Approaches

Publications & Presentations

Press Releases

Events & Presentations

Corporate Governance

Stock Information

Job Openings

Our Community

Core Values

Disclosures

Shareholder Services

Voyager’s leaders bring deep expertise in biopharmaceutical development, neurotherapeutics, genetic medicines, strategic management, and organizational culture. The result is a company delivering on its breakthroughs.

Alfred Sandrock, M.D., Ph.D.

President and Chief Executive Officer

Todd Carter, Ph.D.

Chief Scientific Officer

Jacquelyn Fahey Sandell

Chief Legal Officer

Toby Ferguson, M.D., Ph.D.

Chief Medical Officer

Trista Morrison

Chief Corporate Affairs Officer and Chief of Staff to the CEO

Michelle Quinn Smith

Chief Human Resources Officer

Robin Swartz

Chief Operating Officer, Principal Financial Officer, and Acting Chief Business Officer

Michael Higgins

Grace E. Colón, Ph.D.

James Geraghty

Steven Hyman, M.D

Catherine J. Mackey, Ph.D.

Jude Onyia, Ph.D.

Glenn Pierce, M.D., Ph.D.

George Scangos, Ph.D.

Nancy Vitale

Guangping gao, ph.d..

Director, University of Massachusetts Medical School (UMMS) Gene Therapy Center & Vector Core; Scientific Director, UMMS-China Program Office; Professor of Molecular Genetics and Microbiology, UMMS.

Dinah Sah, Ph.D.

Former Chief Scientific Officer of Voyager and former Vice President of Research at Alnylam Pharmaceuticals.

Phillip Zamore, Ph.D.

Howard Hughes Medical Institute Investigator; Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the RNA Therapeutics Institute, University of Massachusetts Medical School.

Sandrock has been President and Chief Executive Officer of Voyager, as well as a member of the board of directors, since 2022. He also currently serves as a member of the board of directors for Atalanta Therapeutics, Inc.; Verge Genomics, Inc.; Transition Bio, Inc.; and Neurimmune, Inc. Sandrock joined Voyager following a prolific career in biopharmaceutical drug development, in which he spent 23 years at Biogen where he identified and developed novel therapies for a variety of serious diseases. While at Biogen, Sandrock served in positions of increasing responsibility, culminating in his service as Executive Vice President, Research and Development. He also served as Chief Medical Officer and held a seat on the Biogen Executive Committee. Over the course of his tenure, he led the discovery and development, and regulatory approval of numerous medicines including: ADUHELM™, PLEGRIDY®, SPINRAZA®, TECFIDERA®, and TYSABRI®. Sandrock earned a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in neuromuscular disease and clinical neurophysiology at Massachusetts General Hospital.

Carter has been Chief Scientific Officer at Voyager since 2022. Starting in 2016 and prior to his role as CSO, Carter held roles of increasing responsibility at Voyager, most recently serving as senior vice president of research. He led novel gene therapy development programs and supported the development of the TRACER™ platform, the identification of novel AAV capsids, and the execution of multiple successful industry partnerships. Before joining Voyager, Carter served as the Senior Science Advisor to the Office of the Director of the Broad Institute of the Massachusetts Institute of Technology and Harvard, where he was the lead scientific advisor and manager for several internal and external science programs, with a focus on moving innovative science concepts toward the clinic. Previously, he oversaw research at BrainCells, Inc., as Senior Director of Biology, including evaluation of novel targets for CNS disease and the preclinical to clinical transition of the company’s lead program. Carter received a B.A. in genetics from Texas A&M University, a Ph.D. in genetics from Columbia University, and completed his postdoctoral training at the Salk Institute for Biomedical Research.

Fahey Sandell joined Voyager in 2023 as Chief Legal Officer. She has over 25 years of legal experience spanning in-house roles at multiple biotechnology and pharmaceutical companies. Prior to joining Voyager, she served as CLO, Corporate Secretary, and Compliance Officer of Jounce Therapeutics, Inc., where she was responsible for all legal matters, including supporting key license agreements with Gilead and the company’s merger agreement with Concentra Biosciences, LLC. Prior to joining Jounce, Fahey Sandell served as Vice President, General Counsel, Corporate Secretary and Compliance Officer at Vericel Corporation. Fahey Sandell previously held legal positions of increasing seniority at Millennium: The Takeda Oncology Company and Genzyme Corporation, and she has worked at multiple top-tier law firms. Fahey Sandell holds a B.A. from Duke University and a J.D. from Boston University School of Law.

Ferguson has been Chief Medical Officer at Voyager since joining the company in 2024. Ferguson held positions of increasing responsibility at Biogen, most recently serving as Vice President, Head of Neuromuscular Development Unit. During his tenure, he built and developed teams focused on neuromuscular and movement disorders, overseeing strategy for these areas across Biogen R&D. Notably, he led the team that developed QALSODY® (tofersen), the first genetically targeted therapy for SOD1 amyotrophic lateral sclerosis (ALS); this therapeutic received the first accelerated approval based on reduction of neurofilament, a surrogate biomarker pioneered by Ferguson, his team, and the broader ALS community. Overall, his teams at Biogen were responsible for nine successfully executed INDs and three proof-of-concept clinical trials and filings. Prior to joining Biogen, Ferguson was Assistant Professor of Neurology, Shriners Pediatric Research Center and Temple University School of Medicine. He received his M.D. and Ph.D. from University of Florida College of Medicine and his B.S. from University of Florida, Gainesville. He also completed a residency in neurology and a neuromuscular fellowship at the University of Pennsylvania.

Swartz has served as Voyager’s Chief Operating Officer since 2022. She joined the company in 2021 as Senior Vice President, Portfolio Management and Patient Engagement. Prior to joining Voyager, she held several leadership positions at Genzyme Corporation and Sanofi Genzyme. She most recently served as Vice President, Patient and Product Services for Rare Diseases at Sanofi Genzyme and has held various additional positions including as Senior Vice President, Head of Global and U.S. Business Operations, and Chief of Staff to the Executive Vice President and Senior Director, Finance. Swartz served on the Sanofi Aventis Board of Directors and was a member of the Executive Community Relations Committee. Swartz received her B.A. in political science and government from Kenyon College.

Higgins has served on the board of directors since 2015 and as chairman of the board since 2019. He is currently also the chairman of the board of directors of Pulmatrix, Inc. and at Nocion Therapeutics, Inc. He also serves as a board member of Cyclerion Therapeutics, Inc.; Camp4 Therapeutics, Corp.; and Sea Pharmaceuticals, LLC. Higgins is a serial entrepreneur who has helped launch and build numerous companies during his career. He previously served as Entrepreneur-in-Residence at Polaris Partners. He also served as Senior Vice President, Chief Operating Officer of Ironwood Pharmaceuticals, Inc., and held a variety of senior business positions at Genzyme Corp., including Vice President of Corporate Finance and Vice President of Business Development. Higgins received a B.S. from Cornell University and an M.B.A. from the Amos Tuck School of Business at Dartmouth College.

Colón has been a member of Voyager’s board of directors since 2023. She serves as chair of the boards of directors of Bloom Science, Inc. and Emm Technology Ltd. She also serves as a member of the boards of directors of CareDx, Inc.; the Massachusetts Institute of Technology (MIT) Corporation (MIT’s Board of Trustees); the Biotechnology Innovation Organization (BIO); and Inaya Therapeutics, Inc. She is also a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). Colón brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology to the Voyager board. She has served as  President, CEO and Director of InCarda Therapeutics, Inc., and as President and CEO of ProterixBio. Previously, among multiple other roles, Colón served as a partner and senior advisor to New Science Ventures LLC., Senior Vice President and founding President of the Industrial Products Division at Precigen, Inc., (formerly Intrexon Corporation), and in various leadership roles at Gilead Sciences, Inc. and Affymetrix, Inc. (acquired by Thermo Fisher Scientific). Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was a National Science Foundation Fellow, and earned a B.S. in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.

Geraghty has served on Voyager’s board of directors since 2014. He also currently serves as chairman of the board of directors of Pieris Pharmaceuticals, Inc. and CanBridge Pharma, and as member of the board of directors of Fulcrum Therapeutics, Inc. and OMass Therapeutics Limited. He was previously an entrepreneur-in-residence at Third Rock Ventures and served earlier as Senior Vice President, North America Strategy and Business Development at Sanofi S.A. Geraghty held wide-ranging leadership positions at Genzyme, Corp., including Senior Vice President International Development and an executive officer, President of Genzyme Europe, General Manager cardiovascular, and Chairman, President and CEO of Genzyme Transgenics (now GTC Biotherapeutics, Inc.). Geraghty received a B.A. from Georgetown University, an M.S from the University of Pennsylvania, and a J.D. from Yale Law School.

Hyman has served on Voyager’s board of directors since 2015. He currently serves as chair of the board of directors of the Charles A. Dana Foundation (NY) and as a director of Cyclerion Therapeutics, Inc. and of the Stanley Center for Psychiatric Research at the Broad Institute of Harvard and MIT. Hyman is also a core faculty member of the Broad Institute and a Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology. Previously, Hyman served as provost of Harvard University, the university’s chief academic officer. Hyman has held various additional roles including director of the U.S. National Institute of Mental Health, various positions with the National Academy of Medicine, the Forum on Neuroscience and Nervous Systems Disorders, and the governing board of the National Research Council. He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, former president of the Society for Neuroscience, former president of the American College of Neuropsychopharmacology, and a Distinguished Life Fellow of the American Psychiatric Association. Hyman received a B.A. from Yale College, an M.A. from the University of Cambridge, which he attended as a Mellon fellow, and an M.D. from Harvard Medical School.

Mackey has served on Voyager’s board of directors since 2022. She also serves as a member of the boards of directors of Avid Bioservices, Inc. and IDEAYA Biosciences, Inc. She is a seasoned life science executive with more than thirty years of operational experience, highlighted by her tenure as Senior Vice President, Global Research & Development, for Pfizer, Inc. During her tenure at Pfizer, Mackey led La Jolla Labs where she oversaw more than 1,000 staff, delivering a steady-state pipeline of more than two dozen development compounds. Prior to her role at Pfizer La Jolla, Mackey led Strategic Alliances at its R&D headquarters, where she gained extensive experience with both corporate and academic partnerships in the U.S. and global markets. Additionally, she led Pfizer’s U.S. R&D efforts in Genomic and Proteomic Sciences, which included biomarker and pharmacogenomics research. Mackey earned her B.S. and Ph.D. in microbiology from Cornell University.

Pierce has been a member of the board of directors since January 2017. He currently serves as entrepreneur-in-residence at Third Rock Ventures LLC. At Third Rock, he co-founded Ambys Medicines, Inc., and served as Chief Medical Officer. Pierce previously served in several roles at Biogen, Inc., including as Senior Vice President leading the hematology, cell and gene therapies division. Prior to Biogen, he served multiple roles in a variety of biopharmaceutical firms, including Bayer, AG; Inspiration Pharma, Ltd; Avigen, Inc.; Selective Genetics, Inc.; and Amgen, Inc., in the areas of tissue regeneration and hematology. Pierce is the co-author of more than 170 scientific papers and an inventor on more than 15 patents. He served on the medical and scientific advisory council, the board of directors and was President of the board of the National Hemophilia Foundation. Pierce also served on the Blood Products Advisory Committee at the FDA and the Committee on Blood Safety and Availability at the U.S. Department of Health and Human Services. He currently serves on the board of directors of the World Federation of Hemophilia and as the organization’s Vice President, Medical. Pierce received B.A. in biology, an M.D. and a Ph.D. in Immunology, all from Case Western Reserve University in Cleveland. He completed his postgraduate training in pathology and hematology research at Washington University in St. Louis.

Scangos has served on Voyager’s board of directors since 2023. He also currently serves as a member of the board of directors of Vir Biotechnology, Inc.; Agilent Technologies, Inc.; Octave Bioscience, Inc.; Rezo Therapeutics, Inc.; and the Bay Area chapter of Life Science Cares. Scangos previously served as the President and CEO for Vir, where he helped bring to market drugs for COVID-19 and Ebola. Prior to that, he spent several years as CEO and a member of the board of directors for Biogen, Inc., where he advanced a portfolio of medicines for neurological diseases including Alzheimer’s disease. Before joining Biogen, Scangos served more than a decade as President and CEO of oncology company Exelixis, Inc. Prior to joining industry, Scangos was a Professor of Biology at Johns Hopkins University. He received a B.A. in Biology from Cornell University and a Ph.D. in Microbiology from the University of Massachusetts.

Vitale has served on Voyager’s board of directors since 2020. She is the Chief People Officer at Omada Health, Inc. She is also a member of the board of directors for the Make-A-Wish Foundation and a co-founder of Partners for Wellbeing LLC, a boutique human resources consulting firm for which she previously served as Managing Partner. Previously, Vitale served as Senior Vice President and Chief Human Resource Officer at Genentech, Inc., a member of the Roche Group. Prior to Genentech, she held senior human resources roles at Procter & Gamble and CIGNA, Corp. Vitale received a B.B.A. from the University of Michigan and an M.B.A. from the Goizueta Business School at Emory University.

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

“Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurotherapeutics based on genetically-validated targets,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Nathan’s highly differentiated background integrates operational and strategic leadership, a deep understanding of value creation in the life sciences, and expertise in neuroscience, which will be critical as we advance additional programs into the clinic and build a multi-modality neurotherapeutics company.”

As CFO at Vor Bio, Jorgensen oversaw finance, communications, facilities, GMP, and IT and raised over $400 million in public and private financings. Prior to this, he managed global public and private healthcare investing, including in early-stage biotech companies, for the Qatar Investment Authority, the sovereign wealth fund of the State of Qatar. Previously, Jorgensen led pharma and biotech investing efforts on the all-cap equity healthcare team at Calamos Investments LLC, a diversified global investment firm. Before joining Calamos, he covered mid- and large-cap biotech companies as an equity research analyst at Stifel, Nicolaus & Company, Incorporated. Prior to entering the financial sector, Jorgensen investigated the pathobiology of Parkinson’s disease as a postdoctoral scientist at the Columbia University Irving Medical Center. He received his MBA from the Cornell SC Johnson College of Business, his Ph.D. in neuroscience from the University of Minnesota, and his B.A. from St. John’s University.

“Voyager is advancing a suite of transformative neurogenetic medicines, with multiple opportunities to create value for patients and for shareholders,” said Jorgensen. “I am excited about the possibilities offered by Voyager’s differentiated platform, along with its unparalleled team in the field of neuroscience. The pipeline is poised to tackle the delivery hurdles that have held back progress in neurology, and I look forward to applying my strategic financial expertise to enable the team to execute and deliver on the promise of its tremendous science.”

About Voyager Therapeutics

Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “potential,” “anticipate,” “expect,” “will,” “may,” and other similar expressions are intended to identify forward-looking statements.

For example, all statements Voyager makes regarding the timing and effective date of the appointment of Dr. Jorgensen, the contributions Dr. Jorgensen may make in his role with the Company, and Voyager’s ability to advance additional programs into the clinic and build a multi-modality neurotherapeutics company are forward looking.

All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the continued development of Voyager’s technology platforms, including Voyager’s TRACER platform and its antibody screening technology; the ability to initiate and conduct preclinical studies in animal models; the development by third parties of capsid identification platforms that may be competitive to Voyager’s TRACER capsid discovery platform; Voyager’s ability to create and protect intellectual property rights associated with the TRACER capsid discovery platform, the capsids identified by the platform, and development candidates for Voyager’s pipeline programs; the initiation, timing, conduct and outcomes of Voyager’s preclinical and clinical studies; the possibility or the timing of Voyager’s receipt of program reimbursement, development or commercialization milestones, option exercise, and other payments under Voyager’s existing licensing or collaboration agreements; the ability of Voyager to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to Voyager and the third parties; the ability to attract and retain talented directors, employees, and contractors; and the sufficiency of cash resources to fund its operations and pursue its corporate objectives.

These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Trista Morrison, NACD.DC, [email protected]

Investors: Adam Bero, Ph.D., [email protected]

Media: Brooke Shenkin, [email protected]